Use of THK-5351 tau- PET-imaging as a tool for differential diagnosis in hypokinetic-rigid syndromes suggestive for atypical Parkinsonian syndromes.

Trial Profile

Use of THK-5351 tau- PET-imaging as a tool for differential diagnosis in hypokinetic-rigid syndromes suggestive for atypical Parkinsonian syndromes.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jul 2017

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Multiple system atrophy; Progressive supranuclear palsy
  • Focus Diagnostic use; Therapeutic Use
  • Most Recent Events

    • 14 Jul 2017 New trial record
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top